NO161856C - Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,4-diamino-1,2,5-tiadiazol-derivater. - Google Patents

Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,4-diamino-1,2,5-tiadiazol-derivater.

Info

Publication number
NO161856C
NO161856C NO852519A NO852519A NO161856C NO 161856 C NO161856 C NO 161856C NO 852519 A NO852519 A NO 852519A NO 852519 A NO852519 A NO 852519A NO 161856 C NO161856 C NO 161856C
Authority
NO
Norway
Prior art keywords
diamino
preparation
therapeutic active
analogy procedure
thiadiazol derivatives
Prior art date
Application number
NO852519A
Other languages
English (en)
Norwegian (no)
Other versions
NO161856B (no
NO852519L (no
Inventor
Aldo A Algieri
Ronnie R Crenshaw
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of NO852519L publication Critical patent/NO852519L/no
Priority to NO872504A priority Critical patent/NO164711C/no
Publication of NO161856B publication Critical patent/NO161856B/no
Publication of NO161856C publication Critical patent/NO161856C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/101,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/48Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO852519A 1984-06-22 1985-06-21 Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,4-diamino-1,2,5-tiadiazol-derivater. NO161856C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO872504A NO164711C (no) 1984-06-22 1987-06-16 Etan-diimidamid-derivater.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/623,588 US4644006A (en) 1984-06-22 1984-06-22 Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity

Publications (3)

Publication Number Publication Date
NO852519L NO852519L (no) 1985-12-23
NO161856B NO161856B (no) 1989-06-26
NO161856C true NO161856C (no) 1989-10-04

Family

ID=24498651

Family Applications (1)

Application Number Title Priority Date Filing Date
NO852519A NO161856C (no) 1984-06-22 1985-06-21 Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,4-diamino-1,2,5-tiadiazol-derivater.

Country Status (33)

Country Link
US (1) US4644006A (US06373033-20020416-M00035.png)
JP (2) JPS6118775A (US06373033-20020416-M00035.png)
KR (1) KR900004321B1 (US06373033-20020416-M00035.png)
AR (1) AR240935A1 (US06373033-20020416-M00035.png)
AT (1) AT390790B (US06373033-20020416-M00035.png)
AU (2) AU580605B2 (US06373033-20020416-M00035.png)
BE (1) BE902724A (US06373033-20020416-M00035.png)
CA (2) CA1267412A (US06373033-20020416-M00035.png)
CH (1) CH665210A5 (US06373033-20020416-M00035.png)
CS (1) CS257276B2 (US06373033-20020416-M00035.png)
DD (1) DD240889A5 (US06373033-20020416-M00035.png)
DE (1) DE3522101A1 (US06373033-20020416-M00035.png)
DK (1) DK282885A (US06373033-20020416-M00035.png)
ES (2) ES8702902A1 (US06373033-20020416-M00035.png)
FI (1) FI852405L (US06373033-20020416-M00035.png)
FR (1) FR2566406B1 (US06373033-20020416-M00035.png)
GB (2) GB2161157B (US06373033-20020416-M00035.png)
GR (1) GR851514B (US06373033-20020416-M00035.png)
HU (1) HU193992B (US06373033-20020416-M00035.png)
IE (2) IE57937B1 (US06373033-20020416-M00035.png)
IL (1) IL75567A0 (US06373033-20020416-M00035.png)
IT (1) IT1190372B (US06373033-20020416-M00035.png)
LU (1) LU85969A1 (US06373033-20020416-M00035.png)
NL (1) NL8501766A (US06373033-20020416-M00035.png)
NO (1) NO161856C (US06373033-20020416-M00035.png)
NZ (1) NZ212403A (US06373033-20020416-M00035.png)
OA (1) OA08039A (US06373033-20020416-M00035.png)
PT (1) PT80684B (US06373033-20020416-M00035.png)
SE (1) SE464305B (US06373033-20020416-M00035.png)
SU (1) SU1537136A3 (US06373033-20020416-M00035.png)
YU (2) YU45725B (US06373033-20020416-M00035.png)
ZA (1) ZA854710B (US06373033-20020416-M00035.png)
ZW (1) ZW10385A1 (US06373033-20020416-M00035.png)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0535227A4 (en) * 1990-05-29 1993-08-18 Nippon Soda Co., Ltd. N-substituted heterocyclic amidine derivative
US20230349922A1 (en) 2020-08-11 2023-11-02 Université De Strasbourg H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657237A (en) * 1968-05-22 1972-04-18 Frosst & Co Charles E Process for making 1 2 5-thiadiazoles in the sinister configuration
FI76795C (fi) * 1979-09-04 1988-12-12 Bristol Myers Co Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara 3,4-disubstituerade 1,2,5-tiadiazol-1-oxider och -1,1-dioxider samt nya mellanprodukter.
DE3175201D1 (en) * 1980-04-30 1986-10-02 Merck & Co Inc Aminothiadiazoles as gastric secretion inhibitors
US4394508A (en) * 1980-06-07 1983-07-19 Bristol-Myers Company Chemical compounds
EP0045155B1 (en) * 1980-07-30 1985-01-02 Imperial Chemical Industries Plc Guanidine derivatives
EP0060730A3 (en) * 1981-03-18 1982-12-08 Imperial Chemical Industries Plc Bicyclic derivatives
EP0065823A1 (en) * 1981-05-13 1982-12-01 Imperial Chemical Industries Plc Heterocyclic guanidines as histamine H-2 antagonists
US4528378A (en) * 1982-03-29 1985-07-09 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
US4588826A (en) * 1982-03-29 1986-05-13 Bristol-Myers Company Ethanediimidamide intermediates
US4517366A (en) * 1982-03-29 1985-05-14 Bristol-Myers Company Intermediates for preparing 3,4-diamino-1,2,5-thiadiazoles
US4528377A (en) * 1982-03-29 1985-07-09 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
ES8404683A1 (es) * 1982-03-29 1984-05-16 Bristol Myers Co Un procedimiento para la preparacion de antagonistas de los receptores hidrogeno de la histamina.
US4528375A (en) * 1982-03-29 1985-07-09 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
FI832519L (fi) * 1982-07-12 1984-01-13 Bristol Myers Co Farmaceutiska foerfaranden och sammansaettningar
US4520025A (en) * 1982-07-21 1985-05-28 William H. Rorer, Inc. Bicyclic nitrogen heterocyclic ethers and thioethers, and their pharmaceutical uses
JPS5978171A (ja) * 1982-10-26 1984-05-04 Ikeda Mohandou:Kk 複素環式化合物
US4440933A (en) * 1983-03-16 1984-04-03 Bristol-Myers Company Process for preparing 1,2,5-thiadiazoles

Also Published As

Publication number Publication date
FI852405L (fi) 1985-12-23
DD240889A5 (de) 1986-11-19
BE902724A (fr) 1985-12-23
IE58261B1 (en) 1993-08-25
AU4392085A (en) 1986-01-02
AU580605B2 (en) 1989-01-19
ZA854710B (en) 1986-02-26
YU105185A (en) 1987-12-31
AT390790B (de) 1990-06-25
AR240935A1 (es) 1991-03-27
FR2566406A1 (fr) 1985-12-27
CH665210A5 (de) 1988-04-29
CA1267412A (en) 1990-04-03
IE57937B1 (en) 1993-05-19
JPS61186369A (ja) 1986-08-20
GB2161157A (en) 1986-01-08
GB8716149D0 (en) 1987-08-12
KR900004321B1 (ko) 1990-06-22
GB2161157B (en) 1988-08-10
NO161856B (no) 1989-06-26
PT80684A (en) 1985-07-01
FR2566406B1 (fr) 1988-01-29
KR860000275A (ko) 1986-01-27
SE8503110D0 (sv) 1985-06-20
CS257276B2 (en) 1988-04-15
ATA185885A (de) 1989-12-15
CS424785A2 (en) 1987-09-17
AU614331B2 (en) 1991-08-29
CA1297875C (en) 1992-03-24
HU193992B (en) 1987-12-28
YU45822B (sh) 1992-07-20
ES8702902A1 (es) 1987-01-16
YU45725B (sh) 1992-07-20
HUT42087A (en) 1987-06-29
IT8521217A0 (it) 1985-06-20
IT1190372B (it) 1988-02-16
NZ212403A (en) 1989-04-26
OA08039A (fr) 1987-01-31
JPS6118775A (ja) 1986-01-27
GB8515749D0 (en) 1985-07-24
LU85969A1 (fr) 1986-01-24
ES8702881A1 (es) 1987-01-16
DE3522101A1 (de) 1986-01-02
ZW10385A1 (en) 1986-02-05
ES551506A0 (es) 1987-01-16
GB2192884A (en) 1988-01-27
IE851557L (en) 1985-12-22
DK282885A (da) 1985-12-23
ES544409A0 (es) 1987-01-16
AU2977589A (en) 1989-06-01
SU1537136A3 (ru) 1990-01-15
DK282885D0 (da) 1985-06-21
US4644006A (en) 1987-02-17
YU102587A (en) 1988-02-29
SE8503110L (sv) 1985-12-23
NO852519L (no) 1985-12-23
GR851514B (US06373033-20020416-M00035.png) 1985-11-25
IL75567A0 (en) 1985-10-31
FI852405A0 (fi) 1985-06-17
NL8501766A (nl) 1986-01-16
GB2192884B (en) 1988-08-10
AR240935A2 (es) 1991-03-27
PT80684B (en) 1987-05-08
SE464305B (sv) 1991-04-08

Similar Documents

Publication Publication Date Title
NO162238C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,4-dihydro-4-oksonaftyridinderivater.
NO166639C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte, basiske 2-aminotetraliner.
NO851949L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminotetralinderivater.
NO163406C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinolinonderivater.
NO162514C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinonderivater.
NO862477D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-arylimidazol-derivater.
NO880182D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1, 2-dihydro-3h-indazol-3h-indazol-3-on-derivater.
NO164097C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-(n-substituert-guanidino)-4-hetero-aryl-tiazol-derivater.
NO152129C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive omega-cyan-1, omega-difenyl-azaalkanderivater
NO166080C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6,8-trifluorkinoliner.
NO164168C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1,7,4-triazolforbindelser.
NO171412C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksatiolan- eller 1,3-ditiolanderivater
NO863671L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-2-heterocykloalkylpyrido(4,3)indoler.
NO166326C (no) Fremgangsmaate ved fremstilling av terapeutisk aktive 3,7-substituerte-8-oxo-5-thia-1-azabicyclo-(4,2,0)oct-2-en-2-carboxylater.
NO164897C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive oxazolidinonderivater.
NO163486C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-oxy-4h-3,1-benzoxazin-4-on-derivater.
NO158941C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 4-piperidino-kinazolinderivater.
NO160079C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-derivater.
NO158739C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-piperazinopyrimidinderivater.
NO165069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklopentyletere.
NO161313C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive fluorallylaminderivater.
NO165104C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive 1, 1-disubstituerte cyklopropanderivater.
NO167807C (no) Analogifremgangsmaate til fremstilling av 3',4'-dinitrogensubstituerte epipodofyllotoksinglukosidderivater.
NO164895C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dikloranilinderivater.
NO162072C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tienopyridinderivater.